Zobrazeno 1 - 10
of 54
pro vyhledávání: ''
Publikováno v:
Neuro-Oncology, vol 23, iss Supplement_6
Neuro Oncol
Neuro Oncol
INTRODUCTION Primary CNS Lymphoma (PCNSL) is a rare and aggressive cancer that originates from lymphocytes and develops in the central nervous system. Standard induction therapy involves high-dose methotrexate (HD-MTX)-based chemotherapy, which achie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::685a261f75fca70eb8993cbc01b4476b
https://escholarship.org/uc/item/6qp0r764
https://escholarship.org/uc/item/6qp0r764
Autor:
Yasuhiro Funahashi, Hiroki Ikezawa, Lucjan Wyrwicz, Richard S. Finn, Masatoshi Kudo, Shukui Qin, Min Ren, Thomas R. Jeffry Evans, Ari David Baron, Roger K.C. Ngan, Yukinori Minoshima, Fabio Piscaglia, Ann-Lii Cheng, Masafumi Ikeda, Arndt Vogel, Corina E. Dutcus, Jean-Frédéric Blanc, R. Dairiki, Toshiyuki Tamai, Kwang Hyub Han, Michio Kanekiyo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 17
Purpose: In REFLECT, lenvatinib demonstrated an effect on overall survival (OS) by confirmation of noninferiority to sorafenib in unresectable hepatocellular carcinoma. This analysis assessed correlations between serum or tissue biomarkers and effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e245abccc423a21d39f4cc905212001
https://escholarship.org/uc/item/9fv0c960
https://escholarship.org/uc/item/9fv0c960
Autor:
Meghan Sri Karuturi, Tara Sanft, Denise A. Yardley, Angela DeMichele, Sibel Blau, Sara A. Hurvitz, Hope S. Rugo, Amy S. Clark, Amelia Zelnak, Aditya Bardia, Das Purkayastha, Cynthia X. Ma, Lowell L. Hart, Stacy L. Moulder
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 15
Purpose: Standard-of-care treatment for metastatic hormone receptor–positive (HR+), HER2-negative (HER2−) breast cancer includes endocrine therapy (ET) combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). Optimal treatment after progr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07d10c70a51cc377dfe2b31a20be89ec
https://escholarship.org/uc/item/0mj128b0
https://escholarship.org/uc/item/0mj128b0
Autor:
Neeraj Agarwal, Judit Kocsis, Charles P. Theuer, Mohamed Darif, Jing Lyu, Sumanta K. Pal, Bonne J. Adams, Mollie deShazo, Kouros Owzar, Thai H. Ho, Toni K. Choueiri, Liz Robertson, Yousef Zakharia, Andrew B. Nixon, Meghara K. Walsh, Russell K. Pachynski, Lajos Géczi, Yingmiao Liu, Alexandr Poprach, Primo N. Lara, Mark D. Starr
Publikováno v:
The oncologist, vol 26, iss 7
Oncologist
Oncologist
Lessons Learned Background Endoglin is an angiogenic receptor expressed on proliferating tumor vessels and renal cell carcinoma (RCC) stem cells that is implicated as a mechanism of resistance to vascular endothelial growth factor receptor (VEGFR) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cb3cefb1fe953ed4cc21558dbfb65ff
https://escholarship.org/uc/item/6xc9d29b
https://escholarship.org/uc/item/6xc9d29b
Autor:
Amy K. LeBlanc, Timothy M. Fan, Heather Wilson-Robles, Corey F. Saba, Janean Fidel, Nicole C. Northrup, Annette N. Smith, Michael O. Childress, Shawna Klahn, Jennifer L. Willcox, David M. Vail, William C. Kisseberth, Megan E. Brown, Lisa G. Barber, Erika L. Krick, Haley Leeper, Kristine Burgess, Chand Khanna, Raelene M. Wouda, Susan E. Lana, Nikolaos Dervisis, Olya Martin, Angela L McCleary-Wheeler, Mary Lynn Higginbotham, J. Paul Woods, Jeffrey N. Bryan, Aswini Cherukuri, Steven E. Suter, Stephanie S Lindley, Daniel L. Gustafson, Brandan G Wustefeld-Janssens, Laura E. Selmic, Kristen M. Weishaar, Brian K. Flesner, Christina Mazcko, Jenna H Burton, Erika P. Berger, Sara D. Allstadt, Antonella Borgatti, Jennifer A. Mahoney, Cheryl E. Balkman, Kaitlin M. Curran, Anthony J. Mutsaers, Cheryl A. London
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 11
Clin Cancer Res
Clin Cancer Res
Purpose: The mTOR pathway has been identified as a key nutrient signaling hub that participates in metastatic progression of high-grade osteosarcoma. Inhibition of mTOR signaling is biologically achievable with sirolimus, and might slow the outgrowth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::733d5a6dd323a4dc1ec07778b41b81ee
https://escholarship.org/uc/item/68n9j044
https://escholarship.org/uc/item/68n9j044
Autor:
Peng Cao, Georgios Batsios, Chloé Najac, Peder E. Z. Larson, Elavarasan Subramani, Céline Taglang, Sabrina M. Ronen, Robert R. Flavell, Pavithra Viswanath, Anne Marie Gillespie, David M. Wilson
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
IntroductionThe pentose phosphate pathway (PPP) is essential for NADPH generation and redox homeostasis in cancer, including glioblastomas. However, the precise contribution to redox and tumor proliferation of the second PPP enzyme 6-phosphogluconola
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::897a5b3f8e946b13cc237ba665667b5d
https://escholarship.org/uc/item/1jx9c6nh
https://escholarship.org/uc/item/1jx9c6nh
Autor:
David J. Benjamin, Brian A. Jonas, Aaron S. Rosenberg, Mehrdad Abedi, Rasmus T. Hoeg, Matthew E. Tenold, Benjamin N Moskoff, Joseph Tuscano
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab124f6e8736f26663a204cb3818f2e5
https://escholarship.org/uc/item/6g52c8jt
https://escholarship.org/uc/item/6g52c8jt
Autor:
Takashi Higuchi, Shree Ram Singh, Masuyo Miyake, Shinji Miwa, Norio Yamamoto, Scott D. Nelson, Hiroyuki Tsuchiya, Sarah M. Dry, Hiroaki Kimura, Tasuku Kiyuna, Robert M. Hoffman, Kentaro Igarashi, Kentaro Miyake, Kei Kawaguchi, Katsuhiro Hayashi, Ming Zhao, Yunfeng Li
Publikováno v:
Translational oncology, vol 13, iss 2
Translational Oncology, Vol 13, Iss 2, Pp 393-400 (2020)
Translational Oncology
Translational Oncology, Vol 13, Iss 2, Pp 393-400 (2020)
Translational Oncology
Adult pleomorphic rhabdomyosarcoma (RMS) is a rare and malignant mesenchymal tumor. Recently, we developed a patient-derived orthotopic xenograft (PDOX) model of adult pleomorphic RMS. In the present study, we evaluated the efficacy of tumor-targetin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f93261a943f4647bcc123d7582124547
https://escholarship.org/uc/item/922426wz
https://escholarship.org/uc/item/922426wz
Autor:
Grant A. McArthur, Keith T. Flaherty, Antoni Ribas, Brigitte Dréno, Axel Hauschild, Yeung-Chul Mun, Paolo A. Ascierto, Qian Zhu, James Larkin, Edward McKenna, Matthew Wongchenko, Yibing Yan, Karl D. Lewis
Publikováno v:
British journal of cancer, vol 121, iss 7
British Journal of Cancer
British Journal of Cancer
Background This pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib. Methods The data were pooled from BR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7aeaeb834816cc035a3378ef44ab139
https://escholarship.org/uc/item/7m887155
https://escholarship.org/uc/item/7m887155
Autor:
Rajni Sharma, Michelle A. Rudek, Razelle Kurzrock, Douglas W. Ball, Rose Parkinson, Enusha Karunsena, Ralph Zinner, Yoonji Ha, Marianna Zahurak, Nilofer S. Azad, Justin A. Bishop, Shabina Ahmed, Barry D. Nelkin, Ashley O'Connor, Steven I. Sherman, Vivek Subbiah, Christopher D. Gocke
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 25, iss 18
Purpose: Differentiated thyroid cancer (DTC) responds to VEGF receptor inhibitors. VEGF signals through RAS/RAF/MEK signaling. We evaluated the safety and efficacy of the VEGF receptor inhibitor pazopanib and MEK inhibitor trametinib in advanced soli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dfb728e49ebb6f8c244609732d4c96f
https://escholarship.org/uc/item/1fm9j97b
https://escholarship.org/uc/item/1fm9j97b